Basic information Safety Supplier Related

TVB-3166

Basic information Safety Supplier Related

TVB-3166 Basic information

Product Name:
TVB-3166
Synonyms:
  • TVB-3166
  • TVB-3166,TVB3166
  • Benzonitrile, 4-[1-[5-(4,5-dimethyl-1H-pyrazol-3-yl)-2,4-dimethylbenzoyl]-3-azetidinyl]-
  • TVB-3166 >=98% (HPLC)
  • 4-(1-(5-(4,5-Dimethyl-1H-pyrazol-3-yl)-2,4-dimethylbenzoyl)azetidin-3-yl)benzonitrile
  • TVB 3166,inhibit,TVB3166,Apoptosis,TVB-3166,Inhibitor,Fatty Acid Synthase (FASN)
  • TVB-3166, 10 mM in DMSO
  • TVB-3166 ,S3576
CAS:
1533438-83-3
MF:
C24H24N4O
MW:
384.47
Mol File:
1533438-83-3.mol
More
Less

TVB-3166 Chemical Properties

Boiling point:
641.5±55.0 °C(Predicted)
Density 
1.26±0.1 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO:5.0(Max Conc. mg/mL);13.0(Max Conc. mM)
form 
powder
pka
14.66±0.50(Predicted)
color 
white to beige
More
Less

TVB-3166 Usage And Synthesis

Uses

TVB-3166 is an orally-available, reversible, and selective fatty acid synthase (FASN) inhibitor with IC50s of 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis, respectively. TVB-3166 induces apoptosis, and inhibits in-vivo xenograft tumor growth[1].

Biochem/physiol Actions

TVB-3166 is a cell-permeable pyrrazole derivative that inhibits cellular palmitate synthesis (IC50 <100 nM) by fatty acid synthase (FASN) keto-reductase activity in a potent and reversible manner (IC50 = 42 nM), effectively inhibiting palmitate-dependent survival of various cancer cells in cultures and xenografted tumor growth in mice vivo (60-100 mg/kg/d p.o.), while exhibiting little or no anti-proliferation activity toward non-palmitate-dependent growth of cancer and non-cancer cultures. FASN inhibition by TVB-3166 treatment is also effective against the replications respiratory viruses both in cultures (Effc. conc. 200 nM against RSV and PIV3 in A549, HEp2, and HeLa cultures) and in mice (50 mg/kg/12 h, p.o.; RSV) in vivo without significant adverse effects to the host cells or mice.

in vivo

TVB-3166 (Oral gavage; 30-100 mg/kg/day) inhibits xenograft tumor growth[1].
TVB-3166 (Oral gavage; 30-100 mg/kg/day) has the concentration is approximately 3-fold higher in plasma than tumor. The 100 and 30 mg/kg groups had plasma and tumor concentrations of 7 and 2.9 μM, respectively[1].

Animal Model:Female BALB-c-nude mice[1]
Dosage:30, 60, or 100 mg/kg
Administration:Oral gavage; once daily
Result:Inhibited xenograft tumor growth.
Animal Model:Female BALB-c-nude mice[1]
Dosage:30, 60, or 100 mg/kg (Pharmacokinetic Study)
Administration:Oral gavage; once daily
Result:The concentration was approximately 3-fold higher in plasma than tumor. The 100 and 30 mg/kg groups had plasma and tumor concentrations of 7 and 2.9 μM, respectively.

References

[1] Ventura R, et al. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression. EBioMedicine. 2015 Jul 2;2(8):808-24. DOI:10.1016/j.ebiom.2015.06.020

TVB-3166Supplier

Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Email
isunpharm@qq.com
Shanghai XingMo Biotechnology Co., Ltd.
Tel
+86 13524779951; 13524779951
Email
2075692521@qq.com
Sigma-Aldrich
Tel
021-61415566 800-8193336
Email
orderCN@merckgroup.com
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
Shanghaizehan biopharma technology co., Ltd.
Tel
021-61350663 13052117465
Email
sales@zehanbiopharma.com